Trial Profile

Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 24 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darunavir (Primary) ; Rifampicin; Ritonavir
Indications HIV-1 infections
Focus Pharmacokinetics
Acronyms Darifi

Most Recent Events

18 May 2022 Results evaluating the pharmacokinetics of DRV, ritonavir , and DTG, in the presence and absence of RIF in peripheral blood mononuclear cellspublished in the Antimicrobial Agents and Chemotherapy
10 Mar 2021 Primary endpoint has been met. (Darunavir plasma concentrations nanogram per milliliter (ng/ml) with rifampicin), as per Results presented at the 28th Conference on Retroviruses and Opportunistic Infections
10 Mar 2021 Results presented at the 28th Conference on Retroviruses and Opportunistic Infections

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com